Literature DB >> 8199990

Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer.

A Zerbi1, V Fossati, D Parolini, M Carlucci, G Balzano, G Bordogna, C Staudacher, V Di Carlo.   

Abstract

BACKGROUND: Local recurrence is the most frequent site of failure after resection for pancreatic cancer. Tolerance, local control, and survival obtained by the association of resection and intraoperative radiation therapy (IORT) were reported.
METHODS: Between June 1985 and March 1993, 90 resections for pancreatic cancer were performed at the authors' institution. For 43 patients, IORT was added to resection (Group 1), whereas the other 47 patients underwent resection alone (Group 2), because of either the unavailability of linear accelerator or the patient's refusal. In Group 1, radiation doses from 12.5 to 20 Gy, with electron beam energies between 6 and 12 MeV, were delivered. Extension of the disease was similar in the two groups of patients: mean diameter of the tumor was 3.2 cm in Group 1 and 3.4 cm in Group 2; percentage of third degree stage disease (International Union Against Cancer classification) was 65.1% in Group 1 and 57.4% in Group 2; and tumor clearance was incomplete in 39.5% of patients in Group 1 and in 34.0% in Group 2.
RESULTS: Operative mortality and overall early post-operative complications were respectively 2.3% and 23.2% in Group 1 and 2.1% and 23.4% in Group 2. One-year, 2-year, and 3-year survival rates were respectively 71%, 24%, and 7% in Group 1 and 49%, 16%, and 10% in Group 2 (P was not significant). Median disease free survival was 13 months in Group 1 and 8 months in Group 2 (P was not significant). A local recurrence was detected in 27.0% of patients in Group 1 and in 56.4% of patients in Group 2 (P < 0.01).
CONCLUSIONS: The results suggest a better local control in patients with pancreatic cancer undergoing adjuvant IORT.

Entities:  

Mesh:

Year:  1994        PMID: 8199990     DOI: 10.1002/1097-0142(19940615)73:12<2930::aid-cncr2820731209>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

Review 1.  Adjuvant therapy in pancreatic cancer.

Authors:  P Ghaneh; J Slavin; R Sutton; M Hartley; J P Neoptolemos
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 2.  Adjuvant and neoadjuvant therapies of pancreatic cancer: a review.

Authors:  J Harris; H Bruckner
Journal:  Int J Pancreatol       Date:  2001

Review 3.  Current and future strategies for combined-modality therapy in pancreatic cancer.

Authors:  Andrew H Ko; Margaret A Tempero
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

Review 4.  Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer.

Authors:  D Birk; H G Beger
Journal:  Curr Gastroenterol Rep       Date:  2001-04

5.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 6.  Neoadjuvant radiotherapeutic strategies in pancreatic cancer.

Authors:  Falk Roeder
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

7.  Intraoperative and postoperative radiotherapy in pancreatic cancer.

Authors:  V Di Carlo; A Zerbi; G Balzano; E Villa
Journal:  Int J Pancreatol       Date:  1997-02

Review 8.  Results of adjuvant therapy in resected pancreatic cancer.

Authors:  A Andrén-Sandberg; P L Bäckman; R Andersson
Journal:  Int J Pancreatol       Date:  1997-02

9.  In vitro chemosensitivity of human pancreatic cancer cell lines.

Authors:  Y Sawabe; H Yamagishi; N Yamaguchi; Y Yamamura; T Oka
Journal:  Int J Pancreatol       Date:  1996-12

Review 10.  Adjuvant therapy in pancreatic cancer: a critical appraisal.

Authors:  Helmut Oettle; Peter Neuhaus
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.